Convenient options for patients to access ZELSUVMI
At-home delivery using Amazon Pharmacy
(ePrescribe NPI: 1821438862)
Local pharmacy
(eg, Walgreens)
ASPN Pharmacy
(ePrescribe NPI: 1538590690)
Copay assistance program
Patients with commercial insurance may be eligible to receive ZELSUVMI for as little as $0*
Direct patients here to enroll:
Enroll NowSupport to help patients move forward with treatment
Whether just starting treatment or answering questions along the way, ZelsuvmiGO is designed to support patients with resources and personalized assistance
Financial support options
Copay assistance program to help manage out-of-pocket costs
Patient assistance program (PAP) enrollment
Help for patients who are uninsured or whose insurance does not cover ZELSUVMI
Prescription reminders and refill scheduling
Set up helpful alerts so patients never miss a dose
Insurance coverage support
Connect with our team for answers about treatment, coverage, and more
Visit zelsuvmi.com/support or call ZelsuvmiGO at (888) 309-0186.
Patients are not eligible for copay savings if they participate in a state- or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs healthcare, or a state prescription drug assistance program. Commercially insured patients on a plan that does not cover ZELSUVMI are also not eligible. Program terms and conditions apply. Visit zelsuvmi.com/copay for complete terms and conditions.
INDICATION
ZELSUVMI is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 1 year of age and older.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Application site reactions, including allergic contact dermatitis, have occurred in patients treated with ZELSUVMI. Suspect allergic contact dermatitis in the event of pain, pruritus, swelling, or erythema at the application site lasting longer than 24 hours. If allergic contact dermatitis occurs, discontinue ZELSUVMI and initiate appropriate therapy.
ADVERSE REACTIONS
The most commonly reported adverse reactions (incidence ≥1%) are application site reactions, including pain (such as burning or stinging sensations, 18.7%), erythema (11.7%), pruritus (5.7%), exfoliation (5.0%), dermatitis (4.9%), swelling (3.5%), erosion (1.6%), discoloration (1.5%), vesicles (1.5%), irritation (1.2%), and infection (1.1%). Other adverse reactions include pyrexia (2.2%), vomiting (1.3%), and upper respiratory tract infection (1.2%).
USE IN SPECIFIC POPULATIONS
Pregnancy: There are no available data with use of ZELSUVMI in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Lactation: There are no data on the presence of berdazimer in human or animal milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZELSUVMI and potential adverse effects on the breastfed child.
Pediatric: The safety and effectiveness of ZELSUVMI have not been established in pediatric patients younger than 1 year of age.
To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may request medical information and report adverse events or product complaints to Pelthos Inc. by calling 1-855-330-7546 or sending an email to medinfo@pelthos.com.
Please see the full Prescribing Information and Instructions for Use for ZELSUVMI.